Natera (NASDAQ:NTRA) Issues Quarterly Earnings Results, Beats Estimates By $0.39 EPS

Natera (NASDAQ:NTRA) announced its earnings results on Thursday. The medical research company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.69) by $0.39, Briefing.com reports. Natera had a negative net margin of 30.24% and a negative return on equity of 49.72%. The business had revenue of $413.35 million during the quarter, compared to analysts’ expectations of $343.00 million. During the same quarter in the prior year, the company posted ($0.97) earnings per share. The firm’s revenue was up 58.1% on a year-over-year basis. Natera updated its FY 2024 guidance to EPS.

Natera Price Performance

NTRA stock traded up $6.87 during mid-day trading on Friday, hitting $114.57. The stock had a trading volume of 4,125,245 shares, compared to its average volume of 1,404,851. The company has a current ratio of 4.12, a quick ratio of 3.98 and a debt-to-equity ratio of 0.36. Natera has a 52 week low of $36.90 and a 52 week high of $117.39. The firm has a market capitalization of $14.07 billion, a P/E ratio of -36.72 and a beta of 1.48. The firm has a fifty day simple moving average of $107.91 and a 200 day simple moving average of $95.17.

Insider Buying and Selling at Natera

In other Natera news, CEO Steven Leonard Chapman sold 5,496 shares of the firm’s stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $111.66, for a total value of $613,683.36. Following the transaction, the chief executive officer now directly owns 207,855 shares of the company’s stock, valued at approximately $23,209,089.30. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In related news, CFO Michael Burkes Brophy sold 1,866 shares of Natera stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $99.65, for a total transaction of $185,946.90. Following the sale, the chief financial officer now directly owns 71,955 shares of the company’s stock, valued at approximately $7,170,315.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Steven Leonard Chapman sold 5,496 shares of Natera stock in a transaction that occurred on Monday, July 15th. The shares were sold at an average price of $111.66, for a total transaction of $613,683.36. Following the sale, the chief executive officer now directly owns 207,855 shares in the company, valued at $23,209,089.30. The disclosure for this sale can be found here. Insiders have sold a total of 88,387 shares of company stock valued at $9,547,136 in the last ninety days. 7.60% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

NTRA has been the topic of several analyst reports. StockNews.com raised shares of Natera from a “sell” rating to a “hold” rating in a research report on Friday, May 17th. Robert W. Baird upped their price target on shares of Natera from $117.00 to $120.00 and gave the stock an “outperform” rating in a research report on Friday. Stephens reaffirmed an “overweight” rating and set a $125.00 price target on shares of Natera in a research report on Friday. The Goldman Sachs Group upped their price target on shares of Natera from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Monday, April 15th. Finally, Piper Sandler upped their price target on shares of Natera from $110.00 to $120.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 14th. One research analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat.com, Natera currently has an average rating of “Moderate Buy” and a consensus price target of $112.80.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.